{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-018717","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.307767+00:00","generated_at":"2026-05-25T23:32:15.778427+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.85,"confidence":"high","headline":"Outlook Therapeutics resubmits BLA for ONS-5010 to FDA","bullets":["Resubmitted Biologics License Application for ONS-5010 to FDA on February 28, 2025.","No details on resubmission content, prior FDA actions, or expected review timeline provided.","Resubmission marks a key regulatory step for the company's sole pipeline candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-018717","json":"https://secwatch.observer/filing/0001104659-25-018717.json","markdown":"https://secwatch.observer/filing/0001104659-25-018717.md","text":"https://secwatch.observer/filing/0001104659-25-018717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925018717/0001104659-25-018717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925018717/tm257885d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T23:32:15.778427+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}